In Q1 FY2026 (ended March 31, 2026), Bicara Therapeutics reported a net loss of $56.2 million, a 52.6% increase from the prior year. Operating loss was $60.2 million, up 44.2% year-over-year. Diluted EPS was -$0.93, compared to -$0.68 in Q1 FY2025. The company held $323.5 million in cash and $514.0 million in equity, with no long-term debt.
•Net loss widened 52.6% to $56.2 million.
•Operating loss increased 44.2% to $60.2 million.
•Diluted EPS of -$0.93 vs. -$0.68 a year ago.
•Cash and equivalents of $323.5 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to human transforming growth factor beta (TGF-β). This innovative approach targets solid tumors by simultaneously engaging two key pathways involved in cancer growth and immune suppression. The company's pipeline is centered on this bifunctional platform, aiming to improve outcomes for patients with difficult-to-treat cancers. As a clinical-stage company, Bicara is primarily engaged in research and development activities to advance its therapeutic candidates through clinical trials.
Where is Bicara Therapeutics Inc. listed and what currency does it trade in?
Bicara Therapeutics Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol BCAX. Its shares are traded in United States Dollars (USD), which is the standard currency for stocks listed on U.S. exchanges. The NasdaqGM is a tier of the Nasdaq stock exchange that lists companies meeting specific financial and liquidity requirements, providing investors with access to a regulated and transparent trading environment. Being listed on a major U.S. exchange like NasdaqGM offers Bicara visibility among institutional and retail investors globally.
What sector and industry does Bicara Therapeutics Inc. belong to?
Bicara Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes, organisms, or cellular systems to develop products and therapies, often focusing on areas like oncology, immunology, and genetic disorders. As a biotechnology firm, Bicara is involved in cutting-edge research and development of novel treatments, particularly bifunctional antibodies for solid tumors. This industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant potential for breakthrough therapies. The Healthcare sector encompasses a wide range of companies, including pharmaceuticals, medical devices, and healthcare services, with biotechnology being a key subsector driving innovation in medicine.
Where is Bicara Therapeutics Inc. headquartered and what is its background?
Bicara Therapeutics Inc. is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2018, making it a relatively young player in the biotechnology space. Boston is a major hub for biotechnology and life sciences, home to numerous research institutions, hospitals, and biotech firms, providing a rich ecosystem for innovation and collaboration. Bicara's focus on developing bifunctional therapies for solid tumors reflects the cutting-edge research often found in this region. The company's incorporation date indicates it has been operating for about six years as of 2024, a typical timeframe for a clinical-stage biotech to advance its lead candidate through early-stage clinical trials.